New immunotherapy combo takes on advanced colorectal cancer

NCT ID NCT06934538

Recruiting now Disease control Sponsor: Brenus Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new immunotherapy called STC-1010 combined with standard chemotherapy and immune boosters in people with advanced colorectal cancer that cannot be removed by surgery. The study has two parts: first, finding the safest dose in about 21-33 participants, then testing how well it works in about 57-60 more. The goal is to see if the treatment can control the cancer and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STC-1010 (an immunotherapy) plus immunostimulants (cyclophosphamide and GM-CSF) and standard chemotherapy (mFOLFOX6 with or without bevacizumab)
What this could lead to: If successful, this could lead to a new treatment option that helps control advanced colorectal cancer and may extend the time without the disease worsening.
What could go wrong: This is an early phase I/IIA trial with a small number of participants, so the treatment may not prove effective or safe in larger studies. Side effects from the immunotherapy and chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE LOCALLY ADVANCED COLORECTAL CANCER UNRESECTABLE/METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Centre Georges François Leclerc (CGFL)
RECRUITING

Dijon, France
Centre Hospitalier Universitaire de Poitiers (CHU)
NOT_YET_RECRUITING

Poitiers, France
Centre Léon Bérard (CLB)
NOT_YET_RECRUITING

Lyon, France
Hospices Civils de Lyon (HCL)
RECRUITING

Lyon, France
Institut Bergonié
RECRUITING

Bordeaux, France
Institut Gustave Roussy (IGR)
RECRUITING

Villejuif, France
Institut Jules Bordet
NOT_YET_RECRUITING

Brussels, Belgium
Institut du Cancer de Montpellier (ICM)
RECRUITING

Montpellier, France
Johns Hopkins
NOT_YET_RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.